Top Oncology Partnering Opportunities: Immunotherapy In Vogue
Every November at Elsevier Business Intelligence’s Therapeutic Area Partnerships meeting in Boston, expert consultants present their pick of the top unpartnered oncology candidates. This year NewLink Genetics, Genelux, and Verastem are among those that made the grade.
You may also be interested in...
Phase I data for immune checkpoint molecules in melanoma from Bristol, Roche and Merck were a major highlight of the ASCO 2013 annual meeting. Considering potential application in many cancers regardless of genetic mutations, some analysts are predicting billions in future sales.
With late-stage assets scarce, Campbell Alliance consultants offer tips for spotting early oncology opportunities, as part of Windhover’s Therapeutic Area Partnerships annual showcase of top unpartnered assets. MEI Pharma, Macrogenics and EnGeneIC are among the companies featured this year.
No longer the odd cousins of traditional pharmaceutical applications, a host of therapeutic cancer vaccines is working through late-stage trials with real, life-extending data already reported and the potential to create a lot of action in the oncology sector.